Medical News

RSS

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

Nippon Product Acquisition commences tender offer to acquire outstanding shares of Home Diagnostics

Nipro Corporation, through its wholly-owned subsidiary Nippon Product Acquisition Corporation (the “Purchaser”), today commenced a cash tender offer to purchase all outstanding shares of Home Diagnostics, Inc. pursuant to an Agreement and Plan of Merger among Nipro, the Purchaser and Home Diagnostics dated February 2, 2010 (the “Merger Agreement”).

11 Feb 2010

RadPharm and Medifacts International announce merger

RadPharm Inc., a leading Imaging Core Laboratory, and Medifacts International, Inc., a leading Cardiovascular Core Laboratory, today announced the merger of their business operations. The combined company will be named CoreLab Partners ("CoreLabs") and will have its corporate headquarters in Princeton, New Jersey.

11 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

IDEXX Laboratories' Board authorizes increase in share repurchase program

IDEXX Laboratories, Inc., announced today that its Board of Directors has authorized the repurchase by the Company of up to an additional four million shares of its common stock under its ongoing share repurchase program.

11 Feb 2010

Cambridge Heart submits 510(k) application for Microvolt T-wave Alternans OEM Module

Cambridge Heart, Inc., today announced that the Company has completed the development phase of its Microvolt T-wave Alternans (MTWA) OEM Module, and has submitted a 510(k) application for regulatory approval with the U.S. Food and Drug Administration (FDA). The module is the centerpiece of the Company’s new business model that involves partnering with leading stress test equipment manufacturers to broaden the distribution and use of MTWA technology.

11 Feb 2010

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for intravenous (IV) acetaminophen.

11 Feb 2010

Biodel's VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel

Biodel, Inc. announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company’s two Phase 3 studies with VIAject® ultra-rapid-acting recombinant human insulin in a platform presentation at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland, on Friday, February 12, 2010, at 1pm central European time.

11 Feb 2010

NovaMed reports total net revenue of $39.8M for fourth-quarter 2009

NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the fourth quarter and year ended December 31, 2009. Total net revenue grew to $39,809,000, up 10% from $36,177,000 in the prior year fourth quarter. Same-facility net revenue growth was 6% for the quarter.

11 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

LabCorp reports financial results for quarter and year ended December 31, 2009

Laboratory Corporation of America® Holdings (LabCorp®) today announced results for the quarter and year ended December 31, 2009.

11 Feb 2010

PHC announces second-quarter fiscal 2010 results

PHC, Inc., d/b/a Pioneer Behavioral Health, “Pioneer” or (the “Company”), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the Company's 2010 second fiscal quarter ended December 31, 2009. The results exclude the operations of the Company`s research division, Pivotal Research Centers, Inc. ("Pivotal"), which was sold during the 2009 third fiscal quarter and was accounted for as a discontinued operation.

11 Feb 2010

China Pediatric Pharmaceuticals issues 375,000 common stock shares in private placement transaction

China Pediatric Pharmaceuticals, Inc., today announced it has recently closed a private placement financing. In the transaction the Company issued 375,000 shares of the Company's common stock at a price of $4.00 per share for an aggregate purchase price of $1.5 million.

11 Feb 2010

Arrowhead Research reports revenue of $148,000 for quarter ended December 31, 2009

Arrowhead Research Corporation today announced financial results for its fiscal 2010 first quarter ended December 31, 2009.

11 Feb 2010

Lack of provider status denies radiation oncologists authority to make decisions based on patient safety and treatment accuracy

Our members deeply regret the needless tragedies outlined in the Times articles and express our sympathy to the families who have lost loved ones and witnessed their suffering. Our hearts also go out to all others whose lives have been impacted by these tragedies including therapists, physicians and physicists. We feel that, as radiation oncology professionals, we are all, directly or indirectly, responsible for these disastrous treatment errors and we therefore must, in future, take a more active role to assure episodes like these are never repeated.

11 Feb 2010

Microbial risk management in food processing needs to be improved within EU countries

Microbial risk management is difficult and very important in food processing and although we have common EU legislation for food producers microbial risk management needs to be improved and harmonized within EU countries. Microbial risk management consists of several parts. Knowledge of hygienic design and factory layout can prevent severe microbial hazards.

11 Feb 2010

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Boston Scientific Corporation today announced a series of management changes and restructuring initiatives designed to strengthen the Company and position it for long-term success.

11 Feb 2010

Golden Meditech announces proposal to change its name into Golden Meditech Holdings

Golden Meditech Company Limited ("Golden Meditech," or "the Group"), China's leading integrated high-tech healthcare business, is pleased to announce today that the Board of Directors ("the Board") has proposed to change the Company's name into "Golden Meditech Holdings Limited", subject to the shareholders' approval at the forthcoming EGM (Extraordinary General Meeting) and confirmation from the Registrar of Companies in the Cayman Islands.

11 Feb 2010

Winter Sports: Tips on proper training, and prevention of injuries and concussions

According to the Centers for Disease Control and Prevention, 46 percent of children admitted to trauma centers for winter sports injuries have been diagnosed with a head injury – the majority of them from snowboarding, sledding, skiing, ice skating or ice hockey. Pediatric sports medicine is a growing field and is a direct response to how active today’s children are in competitive and recreational sports.

11 Feb 2010

Medical News

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Nippon Product Acquisition commences tender offer to acquire outstanding shares of Home Diagnostics

RadPharm and Medifacts International announce merger

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

IDEXX Laboratories' Board authorizes increase in share repurchase program

Cambridge Heart submits 510(k) application for Microvolt T-wave Alternans OEM Module

Cadence Pharmaceuticals' IV acetaminophen NDA receives FDA Complete Response letter

Biodel's VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel

NovaMed reports total net revenue of $39.8M for fourth-quarter 2009

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

LabCorp reports financial results for quarter and year ended December 31, 2009

PHC announces second-quarter fiscal 2010 results

China Pediatric Pharmaceuticals issues 375,000 common stock shares in private placement transaction

Arrowhead Research reports revenue of $148,000 for quarter ended December 31, 2009

Lack of provider status denies radiation oncologists authority to make decisions based on patient safety and treatment accuracy

Microbial risk management in food processing needs to be improved within EU countries

Boston Scientific combines Cardiovascular Group and Cardiac Rhythm Management Group

Golden Meditech announces proposal to change its name into Golden Meditech Holdings

Winter Sports: Tips on proper training, and prevention of injuries and concussions

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News